News & Updates
Showing Oncology articles
Showing
Show Multimedia Only

Elacestrant ups PFS vs SoC ET in ER-positive, HER2-negative advanced breast cancer
06 Jun 2022
byChristina Lau
Elacestrant, a novel oral selective oestrogen receptor (ER) degrader, significantly improves progression-free survival (PFS) vs standard-of-care (SoC) endocrine therapy (ET) in patients with ER-positive, HER2-negative advanced breast cancer whose disease progressed after 1–2 prior lines of ET and a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, results of the phase III EMERALD trial have shown.
06 Jun 2022

Novel biomarkers predict immunotherapy response, side effects in HCC
02 Jun 2022
byJairia Dela Cruz
A team of Singapore-based researchers has identified two blood biomarkers that not only predict clinical response to immune checkpoint inhibitors (ICIs) in hepatocellular carcinoma (HCC) patients but also the incidence of side effects from the same treatment.
02 Jun 2022







